These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 36102132)

  • 21. Tebentafusp as a Promising Drug for the Treatment of Uveal Melanoma.
    Al Balushi K; Al Hadhrami A; Balushi HA; Al Lawati A; Das S
    Curr Drug Targets; 2024; 25(3):149-157. PubMed ID: 38115619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report.
    Reiter S; Schroeder C; Broche J; Sinnberg T; Bonzheim I; Süsskind D; Flatz L; Forschner A
    Front Oncol; 2023; 13():1167791. PubMed ID: 37207136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp.
    Hassel JC; Berking C; Forschner A; Gebhardt C; Heinzerling L; Meier F; Ochsenreither S; Siveke J; Hauschild A; Schadendorf D
    Eur J Cancer; 2023 Sep; 191():112986. PubMed ID: 37595494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tebentafusp in the treatment of metastatic uveal melanoma - the first patient treated in the Czech Republic.
    Klabusay M; Bábková B
    Klin Onkol; 2024; 38(2):134-138. PubMed ID: 38697822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma.
    Fahmy LM; Schreidah CM; McDonnell DE; Carvajal RD; Magro CM; Geskin LJ
    Dermatol Online J; 2023 Dec; 29(6):. PubMed ID: 38478664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tebentafusp: a first-in-class treatment for metastatic uveal melanoma.
    Howlett S; Carter TJ; Shaw HM; Nathan PD
    Ther Adv Med Oncol; 2023; 15():17588359231160140. PubMed ID: 36970111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study.
    Hamid O; Hassel JC; Shoushtari AN; Meier F; Bauer TM; Salama AKS; Kirkwood JM; Ascierto PA; Lorigan PC; Mauch C; Orloff M; Evans TRJ; Holland C; Edukulla R; Abedin SE; Middleton MR
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37286303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations.
    Montazeri K; Pattanayak V; Sullivan RJ
    Drug Des Devel Ther; 2023; 17():333-339. PubMed ID: 36785760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of metastatic uveal melanoma in 2022: improved treatment regimens and improved prognosis.
    Reichstein D; Brock A; Lietman C; McKean M
    Curr Opin Ophthalmol; 2022 Nov; 33(6):585-590. PubMed ID: 36094043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review of bi-specific therapies in uveal melanoma.
    Orloff M; Seedor R; Sato T
    Cancer Gene Ther; 2022 Dec; 29(12):1814-1818. PubMed ID: 35236927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency of HLA-A*02:01 in the Brazilian population and its impact on uveal melanoma systemic treatment.
    de Melo AC; Lucena E; de Oliveira DCM; Viola JPB
    Oncologist; 2024 Aug; 29(8):e1098-e1099. PubMed ID: 38785402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study.
    Tomsitz D; Ruf T; Heppt M; Staeger R; Ramelyte E; Dummer R; Garzarolli M; Meier F; Meier E; Richly H; Gromke T; Siveke JT; Franklin C; Klespe KC; Mauch C; Kilian T; Seegräber M; Schilling B; French LE; Berking C; Heinzerling L
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Uveal melanoma: In the era of new treatments.
    Wespiser M; Neidhardt E; Negrier S
    Cancer Treat Rev; 2023 Sep; 119():102599. PubMed ID: 37473516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Current State of Systemic Therapy of Metastatic Uveal Melanoma.
    Koch EAT; Heppt MV; Berking C
    Am J Clin Dermatol; 2024 Sep; 25(5):691-700. PubMed ID: 38907174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ensuring equity in the era of HLA-restricted cancer therapeutics.
    Smithy JW; Blouin A; Diamond LC; Postow M
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36442912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immuno-oncology approaches in uveal melanoma: tebentafusp and beyond.
    Gerard C; Shum B; Nathan P; Turajlic S
    Immunooncol Technol; 2023 Sep; 19():100386. PubMed ID: 37483658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma.
    Roshardt Prieto NM; Turko P; Zellweger C; Nguyen-Kim TDL; Staeger R; Bellini E; Levesque MP; Dummer R; Ramelyte E
    Melanoma Res; 2024 Apr; 34(2):166-174. PubMed ID: 38126339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment.
    Petzold A; Steeb T; Wessely A; Koch EAT; Vera J; Berking C; Heppt MV
    Cancer Treat Rev; 2023 Apr; 115():102543. PubMed ID: 36931146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful application of chemosaturation with percutaneous hepatic perfusion in metastatic uveal melanoma patient progressing after systemic treatment options: a case report.
    Gunenc D; Ozluk AA; Yıldırım UM; Ascierto PA; Karaca B
    Front Oncol; 2024; 14():1355971. PubMed ID: 38660135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events.
    Koch EAT; Petzold A; Dippel E; Erdmann M; Gesierich A; Gutzmer R; Hassel JC; Haferkamp S; Kähler KC; Kreuzberg N; Leiter U; Loquai C; Meier F; Meissner M; Mohr P; Pföhler C; Rahimi F; Schell B; Terheyden P; Thoms KM; Ugurel S; Ulrich J; Utikal J; Weichenthal M; Ziller F; Berking C; Heppt MV
    Front Immunol; 2024; 15():1395225. PubMed ID: 38915414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.